Cerebral palsy (CP) is the most common cause of childhood disability globally^[@r1]^. It manifests in restricted functional mobility and negatively impacts the quality of life^[@r2]^. Although the primary brain insult is nonprogressive, the secondary musculoskeletal impairments are progressive^[@r3]^. Intramuscular botulinum toxin A (BTX-A) use is widespread in both the upper and lower limbs^[@r4]-[@r7]^. BTX-A impairs the release of acetylcholine at the neuromuscular junction, which in turn reduces the spasticity of skeletal muscle. Single-event multilevel injection, in which several muscles or muscle groups are injected at each session, is a popular practice^[@r4],[@r8]^. Intramuscular BTX-A has been used in the upper limbs of children with CP to manage preoperative and postoperative pain^[@r4],[@r9]^, facilitate nursing^[@r4]^, and achieve functional and/or cosmetic improvement of hand position^[@r4]-[@r6]^. These goals are achieved primarily through reduction of spasticity. Thus, static contracture deformities cannot be treated by BTX-A. Casting, splinting, exercises, and electrical stimulation are adjunctive treatment modalities that aim to potentiate the effect of BTX-A^[@r2],[@r10]-[@r13]^. In a broader context, intramuscular BTX-A injections should be looked at as a part of a multimodal management approach that includes single-event multilevel surgery in the upper^[@r14]^ or lower^[@r15]^ extremities.

There is a lack of consensus in the literature on the use of intramuscular BTX-A in children with CP as to the exact therapeutic indications, treatment goals, optimal dosing, selection of target muscles, and techniques to guide injection, and on its role as an adjunctive treatment (to other treatment modalities)^[@r4],[@r10],[@r12],[@r16],[@r17]^. Furthermore, the presence of a wide array of subjective and objective outcome measures for patient evaluation before and after BTX-A injection complicates evidence extraction and scholarly communication^[@r16],[@r18]^. Most clinical practices relating to BTX-A injection are based on expert opinion^[@r4]^. We therefore conducted a verifiable literature review of the clinical evidence for the use of BTX-A to improve function in the upper extremities of children with CP. To our knowledge, this topic has not been critically appraised in the literature. We formulated the following research questions: (1) What is the evidence for the use of intramuscular BTX-A to improve function of the upper extremities in children with CP? (2) What are the important complications following BTX-A injection?

Materials and Methods
=====================

Literature Search
-----------------

The literature extraction process involved 4 phases: (1) identification, (2) screening, (3) eligibility, and (4) inclusion. To make the most effective use of the online scholarly databases with respect to coverage, recall, and precision, we used a combination of Google Scholar, PubMed, and ScienceDirect^[@r19]^. The choice of the search terms was based on the Medical Subject Headings. To increase the accuracy of our search results, we used the Boolean operators AND, OR, and NOT. We extracted the relevant studies using a combination of words or terms related to (1) patient population, (2) pathology, (3) clinical intervention, and (4) anatomical distribution of pathology. These terms were (Children OR Childhood) AND (Cerebral Palsy OR Static Encephalopathy) AND (Spasticity OR Dyskinesia) AND (Botulinum Toxin Type A Injection OR Botox Injection) AND (Upper Limb OR Upper Extremity).

All authors shared in the selection and data extraction process pertaining to the use of BTX-A for the upper extremities in children with spastic CP (Fig. [1](#f01){ref-type="fig"}). All titles and abstracts were checked for eligibility. Studies were included if they were (1) randomized controlled trials conducted on children and/or adolescents with CP, (2) studies targeting the upper extremities wholly or in conjugation with other anatomical regions, (3) studies in which BTX-A was used as an adjunctive treatment to a primary intervention, and (4) studies in the English language, without date restrictions. Studies were excluded if they were (1) studies conducted on neuromuscular disorders other than CP, (2) studies conducted exclusively on adult patients with CP, (3) studies exclusively targeting anatomical regions other than the upper extremities, (4) studies of other uses of BTX-A (stroke, cosmetic, ophthalmology, intraparotid, etc.), (5) narrative or systematic review articles, (6) experimental studies, or (7) not retrievable in full-text form.

![Schematic representation of the extraction process. BTX-A = botulinum toxin A.](jbjsr-8-e0119-g001){#f01}

Methodological Quality
----------------------

This systematic review was performed in concordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement^[@r20]^. The methodological quality of included studies was assessed according to the Modified Jadad Scale^[@r21],[@r22]^, an easily applicable scale for appraisal of randomized controlled trials that consists of 8 items (randomization if it was reported and appropriate, blinding if it was reported and appropriate, withdrawals/dropouts, methods for assessing adverse effects, methods of statistical analysis, and the inclusion and exclusion criteria for the participants). The total score can range from 0 to 8 points^[@r21],[@r22]^. A score of 5 to 8 was considered to indicate that the study had high quality; 3 to 4, moderate quality; and \<3, poor quality. The level of evidence of the eligible studies was assessed as described by Sackett and Straus, as has been done in a previous review on this subject^[@r23],[@r24]^.

Results
=======

Study Demographics
------------------

All 15 studies included in this systematic review were randomized controlled trials^[@r25]-[@r39]^. Three studies were performed at multiple centers^[@r30],[@r37],[@r39]^. All of the included studies investigated the effect of BTX-A injection in the upper limb(s), and all were conducted on the spastic type of CP in children. All of the studies had Level-II evidence according to Sackett and Straus^[@r23]^. All of the studies were of high quality; 1 study^[@r29]^ scored 8 points on the Modified Jadad Scale, 10 studies^[@r25],[@r27],[@r28],[@r30],[@r31],[@r34],[@r36]-[@r39]^ scored 7 points, 1 study^[@r26]^ scored 6 points, and 3 studies^[@r32],[@r33],[@r35]^ scored 5 points.

Patient Demographics
--------------------

The total number of participants enrolled in the included studies was 499, with 255 in the intervention group (51%) and 244 controls (49%). All participants in the studies had unilateral spastic CP except those in 4 studies^[@r25],[@r29],[@r31],[@r36]^ (27%) with 198 participants (40%) that included a heterogeneous sample of unilateral and bilateral spastic CP. The mean age of participants in the intervention group ranged from 2.6 to 10.7 years among the individual studies. The mean age of participants in the control group ranged from 3.1 to 10.55 years among the individual studies. The studies that reported patient sex included 262 male patients (53% of the total in the 15 studies) and 162 female patients (32%); the remaining 3 studies^[@r33],[@r35],[@r39]^ with 75 patients (15%) did not indicate the sex distribution of the participants. Participant characteristics are detailed in Table I.

###### 

Patient Demographics, Assessment, and Outcomes After BTX-A Injection[\*](#tblfn1){ref-type="table-fn"}

  Study                      No. of Participants   Randomization                                                                        Mean Age *(yr or yr+mo)*                                                      Sex, M:F   Bilateral CP Included[†](#tblfn3){ref-type="table-fn"}   Time of Follow-up Assessment                                                                         Assessment of Spasticity and Muscle Tone          Result Compared with Controls                                                                                                                               Functional Assessment                                                 Result Compared with Controls
  -------------------------- --------------------- ------------------------------------------------------------------------------------ ----------------------------------------------------------------------------- ---------- -------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Corry et al.^[@r25]^       14                    7 treatment, 7 control                                                               9                                                                             5:9        Yes                                                      Baseline and 2 and 12 wk                                                                             Ashworth Scale, ROM, wrist resonance              All scores on these scales improved in treatment group                                                                                                      Grasp and release score, coin pickup for fine motor assessment        Improvement in grasp and release score, but not coin pickup score, in treatment group
  Fehlings et al.^[@r26]^    30                    15 treatment, 15 control                                                             BTX-A, 5.6 ± 2.6; control, 5.3 ± 2.3                                          20:10      No                                                       Baseline and 1, 3, and 6 mo                                                                          MAS, PROM                                         No significant differences between groups                                                                                                                   QUEST, grip strength, PEDI                                            Significant improvement in QUEST and slight improvement in PEDI in treatment group, but no significant difference in grip strength between groups
  Speth et al.^[@r27]^       20                    10 treatment, 10 control                                                             BTX-A, 9.4; control, 9.7                                                      11:9       No                                                       Baseline and 2 and 6 wk and 3, 6, and 9 mo                                                           Ashworth Scale, AROM                              Significant increase in ROM and tone reduction at the wrist in treatment group                                                                              MA, PEDI, 9-hole peg test                                             No significant difference between groups
  Lowe et al.^[@r28]^        42                    21 treatment, 21 control                                                             4                                                                             31:11      No                                                       Baseline and 1, 3, and 6 mo                                                                          Ashworth Scale                                    Significant improvement in degree of spasticity and muscle tone in treatment group                                                                          QUEST, GAS, COPM, PEDI                                                Improvement in all scores except PEDI, which showed nonsignificant difference, in treatment group
  Kawamura et al.^[@r29]^    39                    21 high dose (treatment), 18 low dose (control)                                      Low dose, 3.1; high dose, 2.6                                                 22:17      Yes                                                      Baseline and 1 and 3 mo                                                                              ROM                                               Slight improvement in both groups, but no difference between doses                                                                                          QUEST, GAS, COPM, PEDI, grip strength                                 Small improvement in arm and hand function, but no significant difference between groups on any scale
  Russo et al.^[@r30]^       43                    21 treatment, 22 control                                                             BTX-A, 8.4;OT control, 8.7                                                    23:20      No                                                       Baseline and 3 and 6 mo                                                                              MAS, Tardieu Scale                                Significant improvement in degree of spasticity and muscle tone in treatment group                                                                          AMPS, GAS, self-perception, PEDI, PedQL                               Improvement in GAS at 3 mo after injection, but no difference between groups on any scale at 6 mo
  Wallen et al.^[@r31]^      72                    20 treatment group 1, 20 treatment group 2, 17 control group 1, 15 control group 2   BTX-A + OT, 5+8 ± 3+1;BTX-A, 6+7 ± 3+9;OT, 5+2 ± 2+11; control, 5+11 ± 2+10   46:26      Yes                                                      Baseline, 2 wk, and 3 and 6 mo                                                                       Tardieu Scale, AROM, PROM                         No significant difference between groups in all scales                                                                                                      COPM, GAS, QUEST, MA, PEDI                                            Significant improvement in COPM and GAS, but no significant difference between groups
  Redman et al.^[@r32]^      22                    12 treatment, 10 control                                                             BTX-A, 10.74; control, 10.55                                                  10:12      No                                                       Baseline and 1, 3, and 6 mo                                                                          NM                                                NM                                                                                                                                                          NM                                                                    NM
  Rameckers et al.^[@r33]^   20                    10 treatment, 10 control                                                             9.5                                                                           NM         No                                                       Baseline (2 wk before injection), 2 wk, 3 and 6 mo (end of therapy), and 3 mo after end of therapy   Ashworth Scale, AROM, PROM, SRA                   Improvement in both groups, but no significant difference between groups                                                                                    Isometric generated force, force production error, MA                 No significant difference between groups, and report of weakness caused by BTX-A (treatment group)
  Olesch et al.^[@r34]^      22                    11 treatment, 11 control                                                             3+8                                                                           19:3       No                                                       Primary outcomes, 3 mo; secondary outcomes, 3 and 6 mo later                                         Modified Tardieu Scale                            Significant reduction in muscle tone in treatment group                                                                                                     COPM, GAS, QUEST, PDMS-FM                                             Significant improvement in GAS score in treatment group over control group, but no difference between groups in COPM, QUEST, and PDMS-FM
  Rameckers et al.^[@r35]^   20                    10 treatment, 10 control                                                             9.5                                                                           NM         No                                                       2 wk and 6 mo (end of therapy) and 3 mo after end of therapy                                         Ashworth Scale, SRA, AROM, PROM                   Improvement in both groups, but no significant difference between groups                                                                                    Kinematic analysis (speed, accuracy, end point spread, performance)   Slight increase in speed and performance in BTX-A treatment group
  Koman et al.^[@r36]^       73                    38 treatment, 35 control                                                             BTX-A, 9; control, 9+11                                                       47:26      Yes (45% of treatment group and 49% of control group)    By OT: screening, baseline, and 4, 8, 14, and 20 wk; by physician: baseline and 7, 20, and 27 wk     UERS for assessment of ROM of upper-limb joints   No significant difference between groups in UERS (shoulder, elbow, forearm, or hand), but greater improvement in mean wrist ROM scores in treatment group   MA, HC, Modified HC                                                   Improvement on MA in treatment group (BTX-A) but not in HC and Modified HC
  Ferrari et al.^[@r37]^     27                    11 treatment, 16 control                                                             BTX-A, 7.36; control, 5.51                                                    14:13      No                                                       Baseline and 1, 3, and 6 mo                                                                          MAS, physician rating scale                       No significant difference between groups                                                                                                                    GAS, AHA, grip strength score, PEDI, CA, AK                           Improvement on GAS and AHA scales in treatment group, but decrease in grip strength, in treatment group. PEDI, CA, and AK showed positive results but no significant difference between groups
  Lidman et al.^[@r38]^      20                    10 treatment, 10 control                                                             3+1                                                                           14:6       No                                                       Baseline and 3 mo; rerated at 6 and 9 mo                                                             AROM                                              Significant improvement in AROM in both groups, but no significant difference between groups                                                                AHA, COPM                                                             Improvement on AHA scale in treatment group, but no difference on the COPM between groups
  Speth et al.^[@r39]^       35                    5 treatment group 1, 13 treatment group 2, 11 control group 1, 6 control group 2     7.14                                                                          NM         No                                                       Baseline and 6, 12, 18, and 24 wk                                                                    NM                                                NM                                                                                                                                                          COPM, GAS, AHA, OSAS, AK                                              Increase in amount of use of both hands and OSAS quality scores in the 2 treatment groups. No significant difference between groups regarding AHA. The BITT control group showed significantly better results than the 2 treatment groups on the GAS.

BTX-A = botulinum toxin A, CP = cerebral palsy, ROM = range of motion, PROM = passive ROM, QUEST = Quality of Upper Extremity Skill Test, PEDI = Pediatric Evaluation of Disability Inventory, AROM = active ROM, MA = Melbourne Assessment, GAS = Goal Attainment Scale, COPM = Canadian Occupational Performance Measure, OT = occupational therapy, MAS = Modified Ashworth Scale, AMPS = Assessment of Motor and Process Skill, PedQL = Pediatric Quality of Life, NM = not mentioned, PT = physical therapy, SRA = stretch resistive angle, PDMS-FM = Peabody Motor Scale-Fine Motor, UERS = Upper Extremity Rating Scale, HC = House Classification, AHA = Assistive Hand Assessment, CA = Caregiver Assistance, AK = ABILHSAND-Kids, OSAS = Observational Skill Assessment Scale, and BITT = Bimanual Task-Oriented Therapy.

GMFCS level was reported in only 1 study^[@r28]^.

Interventions
-------------

The BTX-A injection characteristics, including the dose and type and the primary treatment provided with the BTX-A injection, are described in Table II.

###### 

Characteristics, Precautions, and Adjunctive Treatment with BTX-A Injection[\*](#tblfn2){ref-type="table-fn"}

  Study                      Dose and Type                                                                                                                                                                            Injection Placement and Technique                                                                                                                                                                                                      Muscles Injected                                                                                                                                                   Adjunctive Treatment with BTX-A Injection
  -------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------
  Corry et al.^[@r25]^       Botox (Allergan, USA) and (Dysport, Ponton, UK). Total amount injected, 250 U Botox at dose of 4-7 U/kg body weight or 160-400 U Dysport at dose of 8-9 U/kg. Max. dose, 0.4 mL volume   Location of injection determined by anatomical landmarks. EMLA local anesthetic cream (lignocaine)-lidocaine was applied before injection. Light general anesthesia used in 1 case                                                     Biceps, brachialis, FCR, FCU, FDS and FDP, flexor pollicis longus, pronator teres                                                                                  None
  Fehlings et al.^[@r26]^    Botox (Allergan, USA). 2-6 U/kg                                                                                                                                                          Location determined by muscle palpation and anatomical landmarks                                                                                                                                                                       Biceps, pronator teres, FCU, adductor pollicis, finger flexors                                                                                                     OT
  Speth et al.^[@r27]^       Botox (Allergan). Max. per site, 50 U. Max. dose, 400 U                                                                                                                                  Location determined by electrical muscle stimulation. Injection was done under general anesthesia                                                                                                                                      Biceps, brachioradialis, pronator teres, FCU, FCR, flexor pollicis brevis, adductor pollicis                                                                       PT, OT, splinting
  Lowe et al.^[@r28]^        Botox (Allergan). Max. total dose, 8 U/kg, 100 U BTX-A with 5 mL normal saline solution                                                                                                  Location determined by electrical muscle stimulation. A combination of local anesthetic cream with light general anesthesia was used                                                                                                   Elbow flexors, pronator teres, pronator quadratus, wrist flexors, wrist extensors, finger flexors, thumb adductor, thumb opponens, thumb flexors                   OT
  Kawamura et al.^[@r29]^    Botox (Allergan). High-dose group: 1.5 U/kg, max. 20 U/kg. Low-dose group, 30% of above dose                                                                                             Location determined by anatomical landmarks and muscle palpation. Topical anesthetic was applied before injection                                                                                                                      Biceps, brachioradialis, wrist/finger flexors, pronator teres, adductor pollicis, opponens pollicis                                                                OT
  Russo et al.^[@r30]^       Botox (Allergan, Australia). Min. dose, 5.0 U/kg. Max. dose, 11.6 U/kg                                                                                                                   Location determined by electrical muscle stimulation. Injection was done under general anesthesia                                                                                                                                      Elbow and wrist muscles, without specifying particular muscle injected                                                                                             OT
  Wallen et al.^[@r31]^      Botox (Allergan, Australia). Dose per muscle, 0.5-2 U/kg. Max. dose, 12 U/kg                                                                                                             Location determined by electrical muscle stimulation. Injection was done under local anesthesia and nitrous oxide inhalation                                                                                                           Shoulder (pectoralis complex, latissimus dorsi, teres major), pronators, elbow flexors, wrist flexors, finger flexors, and thumb flexors, adductor, and opponens   OT in 1 group, none in another group
  Redman et al.^[@r32]^      BTX-A. Dose per upper limb muscle group, 0.5-2 U/kg. Max. dose, 12 U/kg                                                                                                                  Not mentioned                                                                                                                                                                                                                          Upper limb muscles, without specifying particular muscles                                                                                                          PT, OT
  Rameckers et al.^[@r33]^   Botox (Allergan). Max. per injection site, 50 U. Overall max., 400 U                                                                                                                     Not mentioned                                                                                                                                                                                                                          Adductor pollicis, flexor pollicis brevis, FCU, FCR, pronator teres, brachioradialis, biceps                                                                       PT, OT
  Olesch et al.^[@r34]^      Botox (Allergan, Australia). 10 U/0.1 mL. Total dose depended on weight of child                                                                                                         Location determined by electrical muscle stimulation. Injections was done under light general anesthesia (a short general anesthesia using sevoflurane)                                                                                Biceps, pronator teres, FCU, FCR, adductor pollicis, flexor pollicis longus, FDS, FDP                                                                              OT
  Rameckers et al.^[@r35]^   Botox (Allergan, USA). Max. per injection site, 50 U. Overall max., 400 U                                                                                                                Not mentioned                                                                                                                                                                                                                          Adductor pollicis, flexor pollicis brevis, FCU, FCR, pronator teres, brachioradialis, biceps                                                                       OT
  Koman et al.^[@r36]^       Botox (Allergan). 1.4-12.5 U/kg                                                                                                                                                          Location determined by anatomical landmarks; ultrasound-guided localization for smaller and deeper muscles                                                                                                                             Shoulder, arm, forearm, hand, without specifying particular muscles                                                                                                None
  Ferrari et al.^[@r37]^     Botox (Allergan). Total dose, \<300 U                                                                                                                                                    Location determined by ultrasound-guided muscle localization. Injections were done under light general anesthesia                                                                                                                      Pronator teres, FCU, FCR, adductor pollicis, opponens pollicis, biceps, pectoralis major, FDS, flexor digitorum brevis, subscapularis                              PT, splinting
  Lidman et al.^[@r38]^      Botox (Allergan Norden, Sweden). 3-30 U/mL. Dose was according to size of the muscles, degree of spasticity, and body weight                                                             Injections guided by neuromuscular electrical stimulation using Teflon-coated BTX-A needle. Injections were done under general anesthesia or nitrous oxide sedation after local anesthetic EMLA cream was applied to injection sites   Biceps, brachialis, brachioradialis, pronator teres, pronator quadratus, adductor pollicis, flexor pollicis brevis                                                 OT, splinting
  Speth et al.^[@r39]^       Dysport (Ipsen) or Botox (Allergan). Max. total Dysport dose, 1,000 U per session; max. total Botox dose, 333 U per session                                                              Location determined by electrical stimulation using Teflon-coated needle. Injections were done under general anesthesia                                                                                                                Arm muscles, forearm muscles, intrinsic muscles of the hand. The most frequently injected muscles were the adductor pollicis, FCR, FCU, and pronator teres         Bimanual task-oriented therapy and splinting in 1 group, none in another group

BTX-A = botulinum toxin A, FCR = flexor carpi radialis, FCU = flexor carpi ulnaris, FDS = flexor digitorum superficialis, FDP = flexor digitorum profundus, OT = occupational therapy, and PT = physical therapy.

In 7 studies^[@r27],[@r28],[@r30],[@r31],[@r34],[@r38],[@r39]^, the investigators injected the BTX-A using anatomical landmarks and electrical stimulation of muscles. Three studies^[@r25],[@r26],[@r29]^ with 83 patients (17%) used only anatomical landmarks for muscle localization. Two studies^[@r36],[@r37]^ with 100 patients (20%) used ultrasound for localization. The remaining 3 studies^[@r32],[@r33],[@r35]^ did not report the method of muscle localization. Twelve of the studies specified Botox as the brand name of BTX-A used for the injections; the remaining 2 studies^[@r25],[@r39]^ with 49 patients (10%) used both brand names Botox and Dysport for injection. Only one study^[@r32]^ did not mention the brand name. The doses varied according to the injected muscle size and bulk, body weight, and degree of spasticity. The BTX-A injection was performed during a single session in 12 studies and repeated sessions in 3 studies^[@r30],[@r34],[@r38]^ with 85 patients (17%). Thirteen studies restricted the injection of BTX-A to the upper limb and 2 studies^[@r31],[@r32]^ with 94 patients (19%) performed additional injections of the lower limb muscles on demand.

Only light general anesthesia was used before injection in 2 studies^[@r34],[@r37]^ with 49 patients (10%), only local anesthesia was used in 1 study^[@r29]^ with 39 patients (8%), and a combination of both was used in 4 studies^[@r25],[@r28],[@r31],[@r38]^ with 148 patients (30%). Only general anesthesia was used in 3 studies^[@r27],[@r30],[@r39]^. The remaining 5 studies^[@r26],[@r32],[@r33],[@r35],[@r36]^ did not report the type of anesthesia used before injection.

Some of the participants in 4 studies^[@r25],[@r29],[@r31],[@r36]^ with 198 patients (40%) were diagnosed with bilateral spastic CP. The side to be injected with BTX-A was selected in 3 of these studies^[@r25],[@r29],[@r36]^ according to the degree of spasticity and patient needs; in the remaining study^[@r31]^ with 72 patients (14%), BTX-A was injected in the dominant limb. The biceps, wrist flexors, pronator teres, and adductor pollicis were injected in at least 12 of the studies; the remaining 3 studies^[@r30],[@r32],[@r36]^ referred to the targeted anatomical regions rather than specifying the injected muscles. The shoulder muscles were injected in 3 studies^[@r31],[@r36],[@r37]^ with 172 patients (34%), and the pronator quadratus was injected in 3 studies^[@r28],[@r31],[@r39]^ with 149 patients (30%) (Table II).

The participants in the control group received a placebo injection in 2 studies^[@r25],[@r36]^ and physical therapy (PT) and splinting with placebo in 1 study^[@r37]^. The controls received occupational therapy (OT) in 7 studies^[@r26],[@r28]-[@r31],[@r34],[@r35]^. In 1 study^[@r38]^, the control group received OT with splinting, and in 2 studies^[@r32],[@r33]^ the controls received OT and PT. In 1 study^[@r39]^, the controls received bimanual task-oriented therapy and splinting, and in 1 study^[@r27]^ they received PT, OT, and splinting. Notably, 2 of the above studies^[@r31],[@r39]^ also had an additional control group that did not receive any treatment or placebo injection.

Participants in the intervention group received BTX-A injection without another treatment regimen in 4 studies^[@r25],[@r31],[@r36],[@r39]^ or combined with OT in 7 studies^[@r26],[@r28]-[@r31],[@r34],[@r35]^. In 1 study each, the participants received OT combined with splinting^[@r38]^, PT and splinting^[@r37]^, bimanual task-oriented therapy with splinting^[@r39]^, and PT, OT, and splinting^[@r27]^. In 2 studies^[@r32],[@r33]^, they received OT and PT. One of the above studies^[@r29]^ was a dose comparison (high versus low-dose groups).

Outcome Measures
----------------

Various scales were used for follow-up of the changes in the degree of spasticity or functional changes in the injected limb after BTX-A injection. Eight studies^[@r25]-[@r27],[@r29],[@r31],[@r33],[@r35],[@r38]^ with 235 patients (47%) used range of motion (ROM). Six studies^[@r25]-[@r28],[@r33],[@r35]^ with 146 patients (29%) used the Ashworth Scale. Three studies^[@r26],[@r30],[@r37]^ with 100 patients (20%) used the Modified Ashworth scale (MAS). Two studies^[@r30],[@r31]^ with 115 patients (23%) used the Tardieu Scale, and 1 study^[@r34]^ with 22 patients (4%) used the Modified Tardieu Scale. The stretch resistive angle (SRA) was used in 2 studies^[@r33],[@r35]^ with 40 patients (8%). A physician rating scale of the upper limb was used for assessment of ROM by 1 study^[@r37]^ with 27 patients (5%). The Upper Extremity Rating Scale was used only in 1 study^[@r36]^ with 73 patients (15%). Various functional assessment scales were used: 7 studies^[@r28]-[@r31],[@r34],[@r37],[@r39]^ with 280 patients (56%) used the Goal Attainment Scale (GAS), 7 studies^[@r26]-[@r31],[@r37]^ with 273 patients (55%) used the Pediatric Evaluation of Disability Inventory, 6 studies^[@r28],[@r29],[@r31],[@r34],[@r38],[@r39]^ with 230 patients (46%) used the Canadian Occupational Performance Measure, 5 studies^[@r26],[@r28],[@r29],[@r31],[@r34]^ with 205 patients (41%) used the Quality of Upper Extremity Skill Test, 4 studies^[@r27],[@r31],[@r33],[@r36]^ with 185 patients (37%) used the Melbourne Assessment, and 3 studies^[@r37]-[@r39]^ with 82 patients (16%) used the Assistive Hand Assessment. Additionally, 2 studies^[@r32],[@r36]^ with 95 patients (19%) used health-related quality of life, the House Classification, and the Modified House Classification. The ABILHAND-Kids (AK) was used in 2 studies^[@r37],[@r39]^ with 62 patients (12%). The Assessment of Motor and Process Skills^[@r30]^ (43 patients, 9%), the Fine Motor Scale of the Peabody Motor Scale^[@r34]^ (22 patients, 4%), and Caregiver Assistance^[@r37]^ (27 patients, 5%) were used in 1 study each. The most common scales used for spasticity assessment were ROM and the Ashworth Scale, and the most common scales for functional assessment were the Quality of Upper Extremity Skill Test and the Canadian Occupational Performance Measure (Table I).

Outcomes of BTX-A Injection
---------------------------

Four studies^[@r25],[@r31],[@r36],[@r39]^ with 194 patients (39%) used the BTX-A without additional rehabilitation regimen. They reported that it had a clinically important effect on upper limb function; however, 1 study^[@r25]^ with 14 patients (3%) reported no effect on fine motor activity. Six studies^[@r26],[@r28],[@r30],[@r31],[@r34],[@r38]^ with 229 patients reported that the BTX-A injection plus OT generally had a positive effect on upper extremity function. One study^[@r37]^ also found a beneficial effect of BTX-A plus the adjunctive use of an orthosis and PT. Two studies^[@r28],[@r29]^ examined the effect of BTX-A dose, and they supported the use of a low dose^[@r29]^ and a low dose at a high concentration^[@r28]^ to improve upper extremity function. Three studies^[@r30],[@r32],[@r36]^ with 138 patients (28%) reported no effect of BTX-A injection on health-related quality of life. Three studies^[@r27],[@r33],[@r35]^ with 60 patients (12%) reported no evidence of additional benefit of BTX-A in patients receiving OT to improve the function and strength of the upper extremity. One study^[@r35]^ with 20 patients (4%) reported a positive effect of BTX-A injection on the kinematic outcome measures for speed and performance of alternating tasks. One study^[@r39]^ assessed the effect of BTX-A and bimanual task-oriented therapy, and reported that BTX-A injection had no additional effect on the bimanual performance but did have a positive effect on the quality of movement and amount of use of the upper extremity.

The effect of BTX-A injection on cosmetic appearance of the injected upper limb was reported in 2 studies^[@r25],[@r30]^ with 57 patients (11%). One of them^[@r25]^ reported that it had a positive effect on cosmesis, and the other reported that this positive effect had disappeared at the time of the final 1-year assessment. Self-perception was mentioned in 1 study^[@r30]^, which reported a positive effect of BTX-A injection on body structures, activity participation, and self-perception.

Complications Following BTX-A Injection
---------------------------------------

No serious, life-threatening complications were described in the studies included in this systematic review, but other complications were reported. These complications arose from either anesthesia or BTX-A injection. Complications related to BTX-A injection were reported in 8 studies^[@r25],[@r26],[@r29]-[@r31],[@r34],[@r36],[@r37]^. Nausea and vomiting were reported as complications of general anesthesia in 2 studies, occurring in 4 patients (9%)^[@r30]^ and 5 patients (7%)^[@r31]^. Excessive and clinically appreciable weakness of the injected muscles was reported in 6 studies, occurring in 2 patients (14%)^[@r25]^, 1 patient (3%)^[@r26]^, 5 patients (13%)^[@r29]^, 5 patients (12%)^[@r30]^, 2 patients (9%)^[@r34]^, and 2 patients (3%)^[@r36]^. Influenza-like symptoms (fever, malaise) were reported in 3 studies, occurring in 1 patient (7%)^[@r25]^, 1 patient (2%)^[@r30]^, and 5 patients (7%)^[@r31]^. Upper respiratory tract infection was reported in 1 study, occurring in 4 patients (6%)^[@r31]^. A maculopapular rash after injection was reported in 1 study, occurring in 1 patient (5%)^[@r34]^. General fatigue was reported in 2 studies, occurring in 3 patients (8%)^[@r29]^ and 1 patient (1%)^[@r36]^. Seizures in patients with epilepsy, headache, and depression were reported in 1 study, occurring in 3 patients (7%)^[@r30]^. Soreness of the injected muscles was reported in 2 studies, occurring in 4 patients (6%)^[@r31]^ and 5 patients (7%)^36^; soreness in relation to the placebo injection, rather than BTX-A injection, was reported in 1 study, occurring in 1 patient^[@r37]^. Three studies^[@r27],[@r28],[@r38]^ reported that there were no complications related to BTX-A injection. Four studies^[@r32],[@r33],[@r35],[@r39]^ did not report the complications of injection.

Funding
-------

Allergan donated the BTX-A in 8 studies^[@r25],[@r26],[@r28],[@r30],[@r31],[@r34],[@r36],[@r37]^ with 323 patients (65%). Ipsen donated the Dysport in 1 study^[@r39]^ with 35 patients (7%). Funding in 4 studies^[@r27],[@r29],[@r33],[@r38]^ was provided by other sources. Funding was not mentioned in 2 studies^[@r32],[@r35]^.

Missing Data
------------

Of the 15 eligible studies, 8 (53%) studies^[@r26],[@r30],[@r32],[@r33],[@r35],[@r36],[@r38],[@r39]^ did not report the following: sex distribution in 3 studies^[@r33],[@r35],[@r39]^ with 75 patients (15%), complications of BTX-A injection in 4 studies^[@r32],[@r33],[@r35],[@r39]^, the method of muscle localization before injection in 3 studies^[@r32],[@r33],[@r35]^ with 62 patients (12%), the anesthesia used before injection in 5 studies^[@r26],[@r32],[@r33],[@r35],[@r36]^ with 165 patients (33%), the individual injected muscles in 3 studies^[@r30],[@r32],[@r36]^ with 138 patients (28%), and funding in 2 studies^[@r32],[@r35]^ with 42 patients (8%). The Gross Motor Function Classification System (GMFCS) level was reported in only 1 study^[@r28]^.

Discussion
==========

Summary of Evidence
-------------------

BTX-A is widely used to avoid or delay multilevel orthopaedic surgery in children with CP through correction of the dynamic lever arm deformities^[@r4],[@r8]^. The findings of this systematic review cast doubt on the role of BTX-A as an adjunctive treatment to interventions in children with CP, such as OT and orthotic splinting, especially with regard to functional gains. Nevertheless, there is evidence to support the use of BTX-A as an adjunctive treatment to other PT regimens or placebo to reduce spasticity. Generally, the nonsignificant or rather mixed functional results may in part be attributed to the muscle weakness that may be encountered after botulinum toxin injection.

Strengths and Limitations
-------------------------

Our study has limitations, particularly ones inherent to the features of the included studies. Uncertain and redundant indications for the use of BTX-A in children with CP may strain the health resources in developing countries. In general, the outcome measures used by the studies included in our systematic review were diverse, both among studies and within individual studies. For spasticity assessment, the Ashworth Scale^[@r26],[@r33]^ and ROM^[@r29],[@r31]^ were the most commonly used. The most common scales used for functional outcome measures were the GAS^[@r28]-[@r31],[@r34],[@r37],[@r39]^, Pediatric Evaluation of Disability Inventory^[@r26]-[@r31],[@r37]^, Quality of Upper Extremity Skill Test^[@r28],[@r29]^, and Canadian Occupational Performance Measure^[@r34],[@r38]^. Key quality-of-life outcome measures included health-related quality of life^[@r30],[@r32],[@r36]^ and Caregiver Assistance^[@r37]^. Additionally, the diversity in the techniques of muscle localization and in the BTX-A dose calculation may have had an impact on the quality of evidence extracted. Multilevel and multidirectional extremity deformities are both essential features of children with CP. This adds to the complexity of patient evaluation and management. It is therefore not surprising that subjective patient-reported outcome instruments such as functional scales and quality-of-life questionnaires are being increasingly recognized as pivotal assessment tools^[@r32],[@r36],[@r37]^. In contrast, the objective physician-reported outcome instruments such as joint ROM are becoming less practical assessment tools, especially from a patient's perspective. The types of outcome instruments used in our systematic review conform to the previous observations.

The degree to which the conclusions of a systematic review are valid and generalizable will be dependent on the level of evidence of its original studies. Randomized controlled trials have the highest levels of evidence^[@r40]^. However, case series studies without a control group can yield strong recommendations and generate credible evidence, provided that these studies adopt strict methodological rigor and control sources of bias originating from confounding variables^[@r41]^. Our systematic review comprised randomized controlled trials, which rank high in the evidence hierarchy. Additionally, the eligible studies of this review demonstrated a recognizable degree of methodological rigor. Nevertheless, we believe that the abovementioned inherent study limitations have a negative impact on our ability to derive strong recommendations from this systematic review of randomized controlled trials.

The studies included in this systematic review used a wide array of outcome instruments. This diversity was demonstrated both across different studies and within individual studies. Additionally, there were a number of confounding variables that presented a potential source of bias, especially with regard to the diversity of injection techniques, methods of localization, and regimens used for the control group. Furthermore, the overall results were mixed and occasionally conflicting with respect to different outcome measures used within an individual study. We thus presumed that performing a meta-analysis would not overcome the above inherent design deficiencies and biases of the original studies included in this review. The above criticisms have been echoed in a number of other studies, including 2 large systematic reviews on the use of BTX-A as an adjunctive treatment for limb spasticity in general: namely, the inconclusive evidence at least with respect to some clinical settings, the diversity of confounding variables, and the need for further research to elucidate the lingering research questions^[@r10],[@r16],[@r42]^.

Conclusions
-----------

There is evidence to support the use of BTX-A as an adjunctive treatment to other modalities such as regular PT and OT with regard to reduction of spasticity. With respect to the functional gains, it is extremely difficult to provide clear-cut recommendations on the efficacy of using BTX-A as an adjunctive treatment. The complications were acceptable and did not outweigh the clinical gains incurred.

Recommendations
---------------

The continued use of BTX-A as an adjunctive treatment for the upper limbs of children with spastic CP is encouraged at least with regard to improvement of spasticity and joint mobility. Such improvement would provide a potential advantage for children with CP, especially with regard to delay of the occurrence of fixed contractures.

We encourage the use of validated quality-of-life questionnaires, especially given that they have been less commonly used as subjective assessment tools throughout the studies in this review.

Treatment decisions may need to be individualized on a case-by-case basis, particularly when functional improvement is used as an outcome measure.
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